| CONTACT: Richard R. Current,
Vice President & CFO,
517/372-9200 |
Neogen reports 30% increase
in operating income
LANSING, Mich., Sept. 29, 2004 –
Neogen Corporation (Nasdaq: NEOG) announced today that its operating
income for the first quarter of its 2005 fiscal year, which ended
Aug. 31, jumped 30% from the previous year’s first quarter.
Neogen’s first quarter revenues were $15,212,000 — a
24% increase compared to the prior year.
First quarter net income per share
was $0.19 as compared with $0.16 for the same period last year.
Neogen’s quarterly net income increased 22% to $1,584,000
from $1,302,000 in FY 2004. The quarter marked the 46th consecutive
profitable quarter from operations for the company, and was the
51st of the past 55 quarters when Neogen reported revenue increases
as compared with the previous year.
“The first quarter was a great
start for our new fiscal year,” said James Herbert, Neogen’s
president. “We continued our remarkable quarter-to-quarter
success of consistent growth in sales and profits, and also made
significant progress in implementing our plan to ensure long-term
growth. I’m very proud of our management team and employee
group.”
The first quarter also saw Neogen
continue its progress toward controlling costs to improve operating
results. Sales and marketing expenses dropped to 21% of sales from
last year’s 24%. General and administrative expenses remained
within Neogen’s target range — under 8% of sales, and
gross margins increased for the third straight quarter to 49.3%
of sales. As a result, the company’s operating income increased
to 16% of sales compared with 15% in the prior year.
Neogen’s Animal Safety Division
led the company’s first quarter revenue increase, with sales
up 50% from $5,334,000 in FY 2004 to $8,012,000 in FY 2005. The
November 2003 acquisitions of Hacco and Hess & Clark contributed
substantially to the increase. However, the division also saw significant
sales growth in its veterinary instrument products, up 20% over
last year, and sales of Neogen’s proprietary K-Blue® substrate,
which was up 45%. Sales growth of more than 40% was also achieved
for both BotVax® B and EqStim®, Neogen’s unique vaccines
sold primarily to the professional equine market.
Integrating Hacco’s rodenticides
into Neogen’s sales and marketing group yielded a 18% sales
increase when compared to the same quarter under previous ownership.
Neogen’s veterinary instrument revenues were bolstered by
continuing improvement in sales to veterinary retailers, including
Tractor Supply Company. Sales of Neogen’s D3™ detectable
veterinary needles experienced a strong increase as the needles’
unique combination of durability and detectability continues to
gain market acceptance.
“The quarter provided solid
indications that our cost-saving initiatives are yielding results,”
said Lon Bohannon, Neogen’s chief operating officer. “We
made some strategic decisions in the previous fiscal year that had
a short-term adverse impact on our earnings knowing we would achieve
long-term benefits. In our first quarter, we started to realize
some of those benefits.”
Neogen’s Food Safety Division first quarter revenues were
up 4.4% compared to the prior year. Lower overall sales for general
sanitation products and tests to detect naturally occurring toxins
were offset by sizable increases in sales of Acumedia dehydrated
culture media products, and food safety products to international
markets. Acumedia sales increased 38% overall, led by strong sales
into industrial, pharmaceutical and food safety markets. International
food safety sales jumped 33%, led by a 38% sales growth in Latin
America for products such as rapid test kits for genetically modified
soybeans and test kits to detect harmful pathogens, such as Listeria.
Increasing sales of Acumedia products
led Neogen to a decision to consolidate its outdated Baltimore dehydrated
culture media operations into newly-renovated space in its Lansing,
Mich., facilities. The new facilities and processing equipment are
expected to dramatically improve operating efficiency, and increase
capacity by 300 to 400%. Production of Acumedia products is expected
to be fully integrated into the Lansing facilities before the end
of Neogen’s second fiscal quarter. The move is not expected
to have a material effect on earnings for the current fiscal year.
“Our solid first quarter results
enabled Neogen to improve on its already strong financial position,”
said Richard Current, Neogen’s chief financial officer. “Positive
cash flows allowed us to pay down $1.5 million of long-term debt
and invest more than $700,000 in new facilities and equipment.”
Neogen Corporation develops
and markets products dedicated to food and animal safety. The company’s
Food Safety Division markets dehydrated culture media, and diagnostic
test kits to detect foodborne bacteria, natural toxins, genetic
modifications, food allergens, drug residues, plant diseases and
sanitation concerns. Neogen’s Animal Safety Division markets
a complete line of diagnostics, veterinary instruments, veterinary
pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.
NEOGEN CORPORATION
SUMMARIZED UNAUDITED
CONSOLIDATED OPERATING DATA
(In thousands, except for percentages and per share amounts)
|
|
|
|
|
|
| Revenue |
|
|
Food Safety
|
$7,200 |
$6,899 |
Animal Safety
|
8,012 |
5,334 |
| Total revenue |
15,212 |
12,233 |
| Cost of sales |
7,707 |
5,973 |
Gross margin
|
7,505 |
6,260 |
| Other expenses |
|
|
Sales & marketing
|
3,206 |
2,923 |
Administrative
|
1,151 |
787 |
Research & development
|
718 |
676 |
| Total other expenses |
5,075 |
4,386 |
| Operating income |
2,430 |
1,874 |
| Other revenue |
(11) |
108 |
| Income before tax |
2,419 |
1,982 |
| Income tax |
835 |
680 |
| Net income |
$1,584 |
$1,302 |
| Net income per diluted share |
$0.19 |
$0.16 |
| Other information: |
|
|
Shares to calculate per share
|
8,468 |
8,211 |
Depreciation & amortization
|
$434 |
$301 |
Interest expense
|
24 |
- |
Gross margin (% of sales)
|
49.3% |
51.2% |
Operating income (% of sales)
|
16.0% |
15.3% |
Revenue increase vs. FY 2004
|
24.3% |
|
Net income increase vs. FY 2004
|
21.7% |
|
NEOGEN
CORPORATION SUMMARIZED UNAUDITED
CONSOLIDATED BALANCE SHEET
DATA
(In thousands)
|
|
|
|
|
|
|
| Assets |
|
|
| Current assets |
|
|
Cash & investments
|
$1,585 |
$1,696 |
Accounts receivable
|
10,357 |
9,924 |
Inventory
|
12,383 |
12,374 |
Other current assets
|
1,917 |
2,281 |
| Total current assets |
26,242 |
26,275 |
| Property & equipment |
11,328 |
10,952 |
| Goodwill & other assets |
22,664 |
22,748 |
| Total assets |
$60,234 |
$59,975 |
| |
| Liabilities & Stockholders’ Equity |
|
|
| Current liabilities |
|
|
Accounts payable
|
$2,829 |
$3,063 |
Other current liabilities
|
2,657 |
2,593 |
| Total current liabilities |
5,486 |
5,656 |
| Other liabilities |
4,952 |
6,477 |
Stockholders’ equity—shares out
8,087 in ‘05 & 8,010 in ‘04 |
|
|
49,796 |
47,842 |
| Total liabilities & stockholders’ equity |
$60,234 |
$59,975 |
Certain
portions of this news release that do not relate to historical financial
information
constitute forward-looking statements. These forward-looking statements
are subject
to certain risks and uncertainties. Actual future results and trends
may differ materially from
historical results or those expected depending on a variety of factors
listed in Management's
Discussion and Analysis of Financial Condition and Results of Operations
in the
Company's most recently filed Form 10-K.
|